Which statement best explains why triptans are commonly used after OTC products for acute migraine?

Which statement best explains why triptans are commonly used after OTC products for acute migraine?

• A. They are effective.
• B. They are more expensive than newer agents.
• C. They have no variability in onset and duration.
• D. They always work when other triptans fail.

Answer: (A)

Triptans are used after OTC products because they provide targeted, reliable relief for an acute migraine attack. They work by activating 5-HT1B/1D receptors in the meningeal vessels and the trigeminal system, which leads to constriction of dilated cranial arteries and inhibition of the release of pro-migraine neuropeptides like CGRP. This directly interrupts the migraine cascade, often producing faster and more consistent relief than OTC analgesics, which mainly blunt pain by reducing prostaglandin synthesis. Because of this focused mechanism and proven efficacy, clinicians reserve triptans for when OTCs do not adequately relieve symptoms or when attacks are disabling. They are not universally effective for every patient, and onset and duration vary by agent and route. They also carry contraindications in cardiovascular disease and other risks. The statement that they are simply more expensive or that they always work after other triptans fail isn’t accurate; the key idea is their targeted action and demonstrated effectiveness in acute attacks after OTCs have fallen short.

Triptans are used after OTC products because they provide targeted, reliable relief for an acute migraine attack. They work by activating 5-HT1B/1D receptors in the meningeal vessels and the trigeminal system, which leads to constriction of dilated cranial arteries and inhibition of the release of pro-migraine neuropeptides like CGRP. This directly interrupts the migraine cascade, often producing faster and more consistent relief than OTC analgesics, which mainly blunt pain by reducing prostaglandin synthesis. Because of this focused mechanism and proven efficacy, clinicians reserve triptans for when OTCs do not adequately relieve symptoms or when attacks are disabling. They are not universally effective for every patient, and onset and duration vary by agent and route. They also carry contraindications in cardiovascular disease and other risks. The statement that they are simply more expensive or that they always work after other triptans fail isn’t accurate; the key idea is their targeted action and demonstrated effectiveness in acute attacks after OTCs have fallen short.